These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 15614187

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
    Chen J, Gu LJ, Ying DM, Shen M, Wu HJ.
    Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
    [Abstract] [Full Text] [Related]

  • 4. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
    McIvor RS.
    Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S50-4. PubMed ID: 8971409
    [Abstract] [Full Text] [Related]

  • 5. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
    Jayaram HN, O'Connor A, Grant MR, Yang H, Grieco PA, Cooney DA.
    J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
    [Abstract] [Full Text] [Related]

  • 6. [cDNA microarray analysis of gene expression in acquired methotrexate-resistant of human choriocarcinoma].
    Chen YX, Xie X, Cheng Q.
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):396-9. PubMed ID: 15312324
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: a comparison of methotrexate resistance.
    Braun SE, McIvor RS, Davidson AS, Hanna M, Traycoff CM, Berebetsky DA, Gonin R, Broxmeyer HE, Cornetta K.
    Cancer Gene Ther; 1997 Jun; 4(1):26-32. PubMed ID: 9012448
    [Abstract] [Full Text] [Related]

  • 10. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
    Lu P, Lu Y, Pang K, Wang SB, Chen JQ, Xu HM, Wang JK, Zhao SC.
    Zhonghua Wai Ke Za Zhi; 2005 Aug 01; 43(15):998-1001. PubMed ID: 16194358
    [Abstract] [Full Text] [Related]

  • 11. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis.
    Fotoohi AK, Assaraf YG, Moshfegh A, Hashemi J, Jansen G, Peters GJ, Larsson C, Albertioni F.
    Biochem Pharmacol; 2009 Apr 15; 77(8):1410-7. PubMed ID: 19426680
    [Abstract] [Full Text] [Related]

  • 12. [Double-mutant dihydrofolate reductase gene transfection into bone marrow cells protects mice from chemotherapy].
    Gao HD, Lu P, Lu Y, Pang K, Xu HM, Wang SB, Chen JQ, Zhao SC.
    Zhonghua Zhong Liu Za Zhi; 2006 Aug 15; 28(8):583-5. PubMed ID: 17236551
    [Abstract] [Full Text] [Related]

  • 13. Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase.
    Volpato JP, Fossati E, Pelletier JN.
    J Mol Biol; 2007 Oct 26; 373(3):599-611. PubMed ID: 17868689
    [Abstract] [Full Text] [Related]

  • 14. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG, Boosalis M, Malek K, Waraska K.
    Leuk Res; 2004 Nov 26; 28(11):1137-43. PubMed ID: 15380336
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated bycounterflow elutriation.
    James R, May C, Diers M, Wagner J, McIvor R.
    Bone Marrow Transplant; 1999 Oct 26; 24(8):815-21. PubMed ID: 10516690
    [Abstract] [Full Text] [Related]

  • 16. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.
    Lindgren M, Rosenthal-Aizman K, Saar K, Eiríksdóttir E, Jiang Y, Sassian M, Ostlund P, Hällbrink M, Langel U.
    Biochem Pharmacol; 2006 Feb 14; 71(4):416-25. PubMed ID: 16376307
    [Abstract] [Full Text] [Related]

  • 17. Resistance mechanisms to methotrexate in tumors.
    Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D.
    Stem Cells; 1996 Jan 14; 14(1):5-9. PubMed ID: 8820944
    [Abstract] [Full Text] [Related]

  • 18. Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells.
    Morales C, Ribas M, Aiza G, Peinado MA.
    Oncogene; 2005 Oct 13; 24(45):6842-7. PubMed ID: 16007155
    [Abstract] [Full Text] [Related]

  • 19. Proteomic analysis for the identification of proteins related to methotrexate resistance.
    Feng YX, Bai J, Zhang CY, Fu SB.
    Yi Chuan Xue Bao; 2006 May 13; 33(5):391-6. PubMed ID: 16722333
    [Abstract] [Full Text] [Related]

  • 20. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
    Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP.
    J Natl Cancer Inst; 2007 Jul 18; 99(14):1107-19. PubMed ID: 17623797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.